Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March, 23andMe said ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has been named the successful bidder in the bankruptcy auction for substantially all of the assets of ...

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Hudson Valley company. Tarrytown based Regeneron Pharmaceuticals, Inc. announced on Monday that it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of ...

Under the proposed agreement with Regeneron, the Tarrytown, New York, drugmaker will acquire 23andMe’s assets, including its personal genome service and total health and research services.

Regeneron Pharmaceuticals said Monday it had ... The deal is subject to bankruptcy court and regulatory approvals. The Tarrytown, N.Y.-based biotech said it would continue 23andMe’s consumer ...